Ceforanide |
|
| AHFS/Drugs.com | International Drug Names |
|---|
Routes of administration | Intramuscular |
|---|
| ATC code | |
|---|
|
| Protein binding | 80.6% |
|---|
| Metabolism | Nil |
|---|
| Elimination half-life | 2.6 to 2.98 hours |
|---|
| Excretion | Renal |
|---|
|
(6R,7R)-7-{[2-[2-(aminomethyl)phenyl]acetyl]amino}-3- {[1-(carboxymethyl)tetrazol-5-yl]sulfanylmethyl}-8-oxo- 5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid
|
| CAS Number | |
|---|
| PubChem CID | |
|---|
| DrugBank | |
|---|
| ChemSpider | |
|---|
| UNII | |
|---|
| KEGG | |
|---|
| ChEBI | |
|---|
| ChEMBL | |
|---|
| NIAID ChemDB | |
|---|
| CompTox Dashboard (EPA) | |
|---|
|
| Formula | C20H21N7O6S2 |
|---|
| Molar mass | 519.55 g·mol−1 |
|---|
| 3D model (JSmol) | |
|---|
O=C2N1/C(=C(\CS[C@@H]1[C@@H]2NC(=O)Cc3ccccc3CN)CSc4nnnn4CC(=O)O)C(=O)O
|
InChI=1S/C20H21N7O6S2/c21-6-11-4-2-1-3-10(11)5-13(28)22-15-17(31)27-16(19(32)33)12(8-34-18(15)27)9-35-20-23-24-25-26(20)7-14(29)30/h1-4,15,18H,5-9,21H2,(H,22,28)(H,29,30)(H,32,33)/t15-,18-/m1/s1 YKey:SLAYUXIURFNXPG-CRAIPNDOSA-N Y
|
N Y (what is this?) (verify) |
Ceforanide is a second-generation cephalosporin antibiotic.[1][2][3]
See also
References
Antibacterials active on the cell wall and envelope (J01C-J01D) |
|---|
β-lactams (inhibit synthesis of peptidoglycan layer of bacterial cell wall by binding to and inhibiting PBPs, a group of D-alanyl-D-alanine transpeptidases) | | Penicillins (Penams) | Narrow spectrum | β-lactamase sensitive (1st generation) | |
|---|
β-lactamase resistant (2nd generation) | |
|---|
|
|---|
Extended spectrum | | Aminopenicillins (3rd generation) | |
|---|
| Carboxypenicillins (4th generation) | |
|---|
| Ureidopenicillins (4th generation) | |
|---|
| Other | |
|---|
|
|---|
|
|---|
| Carbapenems / Penems |
- Carbapenems (Ertapenem
- Antipseudomonal (Doripenem
- Imipenem
- Meropenem)
- Biapenem‡
- Panipenem)
- Penems (Faropenem
- Ritipenem§
- Sulopenem)
|
|---|
Cephems Cephalosporins Cephamycins Carbacephems | | 1st generation | |
|---|
| 2nd generation | |
|---|
| 3rd generation | |
|---|
| 4th generation |
- Cefepime
- Cefozopran‡
- Cefpirome
- Cefquinome‡
|
|---|
| 5th generation |
- Ceftaroline fosamil
- Ceftolozane
- Ceftobiprole
|
|---|
| Siderophore | |
|---|
| Veterinary |
- Ceftiofur
- Cefquinome
- Cefovecin
|
|---|
|
|---|
| Monobactams |
- Aztreonam
- Tigemonam‡
- Carumonam‡
- Nocardicin A‡
|
|---|
| β-lactamase inhibitors |
- Penam (Sulbactam
- Tazobactam
- Enmetazobactam)
- Clavam (Clavulanic acid)
- non-β-lactam (Avibactam
- Durlobactam
- Relebactam
- Taniborbactam
- Vaborbactam)
|
|---|
| Combinations |
- Amoxicillin/clavulanic acid#
- Ampicillin/flucloxacillin
- Ampicillin/sulbactam (Sultamicillin)
- Aztreonam/avibactam
- Benzathine benzylpenicillin/procaine benzylpenicillin
- Cefepime/enmetazobactam
- Cefepime/sulbactam
- Cefoperazone/sulbactam
- Ceftazidime/avibactam
- Ceftolozane/tazobactam
- Imipenem/cilastatin#
- Imipenem/cilastatin/relebactam
- Meropenem/vaborbactam
- Panipenem/betamipron
- Piperacillin/tazobactam
- Sulbactam/durlobactam
- Sulopenem/probenecid
- Ticarcillin/clavulanic acid
|
|---|
|
|---|
| Polypeptides | | Lipopeptides |
- Insert into bacterial cell wall causing perforation and depolarization: Daptomycin
- Surfactin
|
|---|
| Other |
- Inhibits PG elongation and crosslinking: Ramoplanin§
|
|---|
|
|---|
| Intracellular |
- Inhibit PG subunit synthesis and transport: NAM synthesis inhibition
- DADAL/AR inhibitors
- bactoprenol inhibitors
|
|---|
| Other |
- Hydrolyze NAM-NAG
- Tyrothricin
- Isoniazid#
- Teixobactin
|
|---|
- #WHO-EM
- ‡Withdrawn from market
- Clinical trials:
- †Phase III
- §Never to phase III
|